Kymera Therapeutics Reports GAAP EPS Beat Despite Revenue Miss
May 5, 2023
Trending News ☀️
Kymera Therapeutics ($NASDAQ:KYMR) is a biopharmaceutical company that discovers and develops new medicines for serious diseases. The company focuses on novel protein homeostasis therapeutic approaches that are designed to control the production, activity, and degradation of disease-causing proteins in patients with genetically-defined diseases or cancers. By harnessing the body’s natural systems of protein homeostasis, Kymera hopes to create medicines that are more powerful, safer and more effective than existing treatments.
Earnings
In its earning report of FY2022 Q4 ending December 31 2022, KYMERA THERAPEUTICS reported 16.14M USD in total revenue and a net income loss of 34.86M USD. This marks a 5.6% increase in total revenue from 12.78M USD in the last 3 years. Despite the revenue miss, KYMERA THERAPEUTICS reported a GAAP earnings per share (EPS) beat this quarter. This is a notable accomplishment considering the challenging market conditions KYMERA THERAPEUTICS has faced over the past few years.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Kymera Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 46.83 | -154.81 | -330.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kymera Therapeutics. More…
| Operations | Investing | Financing |
| -153.09 | 20.52 | 153 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kymera Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 603.13 | 112.98 | 8.91 |
Key Ratios Snapshot
Some of the financial key ratios for Kymera Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 151.8% | – | -330.2% |
| FCF Margin | ROE | ROA |
| -333.0% | -19.3% | -16.0% |
Share Price
On Thursday, the stock opened at $28.7 and closed at $26.2, a plunge of 15.1% from its prior closing price of 30.9. Live Quote…
Analysis
At GoodWhale, we have conducted an analysis of KYMERA THERAPEUTICS and their financials. We have concluded that KYMERA THERAPEUTICS is a medium risk investment in terms of financial and business aspects. Specifically, our Risk Rating has determined that there are 2 risk warnings in their balance sheet and cashflow statement. If you would like to review these risk warnings, simply register with us and we can provide you with the necessary information. More…
Peers
The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.
– Abionyx Pharma ($LTS:0RAG)
Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.
– Shattuck Labs Inc ($NASDAQ:STTK)
Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.
– Prestige BioPharma Ltd ($KOSE:950210)
Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).
Summary
Investors in Kymera Therapeutics were disappointed when their financials reported on the day of their earnings release. As a result, the stock price of the company dropped on the same day. Despite the short-term losses, investors should still consider Kymera Therapeutics for its long-term potential.
With ongoing research and development efforts, the company’s pipeline products have the potential to bring high returns. It is important for investors to monitor Kymera’s progress and analyze risks before investing in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
